From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

RTS,S/AS01 — trade name Mosquirix — is a recombinant protein-based malaria vaccine. Approved for use by European regulators in July 2015, it is the world's first licensed malaria vaccine and also the first vaccine licensed for use against a human parasitic disease of any kind.[1] The RTS,S vaccine was conceived of and created in the late 1980s by scientists working at SmithKline Beecham Biologicals (now GlaxoSmithKline Vaccines) laboratories in Belgium.[2] The vaccine was further developed through a collaboration between GSK and the Walter Reed Army Institute of Research[3] and has been funded in part by the PATH Malaria Vaccine Initiative and the Bill and Melinda Gates Foundation. Its efficacy ranges from 26 to 50% in infants and young children. It is considered to be a milestone advance[by whom?] in the worldwide campaign against malaria. On 23 October 2015, The World Health Organization's Strategic Advisory Group of Experts on Immunization (SAGE) and the Malaria Policy Advisory Committee (MPAC) jointly recommended a pilot implementation of the vaccine in Africa.[4]


Potential malaria vaccines have been an intense area of research since the 1960s.[5] SPf66 was tested extensively in endemic areas in the 1990s, but clinical trials showed it to be insufficiently effective.[6] Other vaccine candidates, targeting the blood-stage of the malaria parasite's life cycle, have also been insufficient on their own.[7] Among several potential vaccines under development that target the pre-erythrocytic stage of the disease, RTS,S has shown the most promising results so far.[8]

RTS,S has been funded, most recently, by the non-profit PATH Malaria Vaccine Initiative (MVI) and GlaxoSmithKline with funding from the Bill and Melinda Gates Foundation.[9]

The RTS,S-based vaccine formulation had previously been demonstrated to be safe, well tolerated, immunogenic, and to potentially confer partial efficacy in both malaria-naive and -experienced adults as well as children.[10]

In November 2012, findings from a Phase III trial of RTS,S reported that it provided modest protection against both clinical and severe malaria in young infants. In October 2013, GlaxoSmithKline (GSK) reported that the RTS,S vaccine reduced the amount of cases amongst young children by almost 50 percent and among infants by around 25 percent, following the conclusion of an 18-month clinical trial. Data showed the protective effect after the 18 months, however, was less than had previously been seen after 12 months.

The EMA approved the RTS,S vaccine in July 2015, with a recommendation that it be used in Africa for babies at risk of getting malaria. RTS,S was the world's first malaria vaccine to get approval for this use.[11][1] After additional regulatory decisions by the World Health Organization, and individual African country governments, a "roll out" of the product could come as early as 2017.

Preliminary research suggests that delayed fractional dosing could increase the vaccine's efficacy up to 86%.[12][13]

On 17 November 2016, WHO announced that the RTS,S vaccine would be rolled out in pilot projects in 3 countries in sub-Saharan Africa. The pilot programme, coordinated by WHO, will assess the extent to which the vaccine’s protective effect shown in advanced clinical trials can be replicated in real-life settings. Specifically, the programme will evaluate the feasibility of delivering the required 4 doses of the vaccine; the impact of the vaccine on lives saved; and the safety of the vaccine in the context of routine use.[14]

Vaccinations are due to begin in 2018 in the three sub-Saharan countries where it first will be rolled out.[citation needed]

Components and mechanism[edit]

The RTS,S vaccine was engineered using genes from the repeat and T-cell epitope in the pre-erythrocytic circumsporozoite protein (CSP) of the Plasmodium falciparum malaria parasite and a viral envelope protein of the hepatitis B virus (HBsAg), to which was added a chemical adjuvant (AS01) to increase the immune system response.[15] Infection is prevented by inducing humoral and cellular immunity, with high antibody titers, that block the parasite from infecting the liver.[16]

The T-cell epitope of CSP is O-fucosylated in Plasmodium falciparum[17][18] and Plasmodium vivax,[19] while the RTS,S vaccine produced in yeast is not.

See also[edit]


  1. ^ a b Walsh, Fergus (24 July 2015). "Malaria vaccine gets 'green light'". BBC. Retrieved 25 July 2015. 
  2. ^ http://www.google.com/patents/EP0614465B1?cl=3Den
  3. ^ Heppner DG, Kester KE, Ockenhouse CF, et al. (2005). "Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research". Vaccine. 23 (17–18): 2243–50. doi:10.1016/j.vaccine.2005.01.142. PMID 15755604. 
  4. ^ http://who.int/mediacentre/news/releases/2015/sage/en/
  5. ^ Hill AV (2011). "Vaccines against malaria". Philos. Trans. R. Soc. Lond. B Biol. Sci. 366 (1579): 2806–14. doi:10.1098/rstb.2011.0091. PMC 3146776Freely accessible. PMID 21893544. 
  6. ^ Graves, Patricia M; Gelband, Hellen (2006). Graves, Patricia M, ed. "Vaccines for preventing malaria (SPf66)". Cochrane Database of Systematic Reviews (2): CD005966. doi:10.1002/14651858.CD005966. PMID 16625647. 
  7. ^ Graves, Patricia M; Gelband, Hellen (2006). Graves, Patricia M, ed. "Vaccines for preventing malaria (blood-stage)". Cochrane Database of Systematic Reviews (4): CD006199. doi:10.1002/14651858.CD006199. PMID 17054281. 
  8. ^ Graves, Patricia M; Gelband, Hellen (2006). Graves, Patricia M, ed. "Vaccines for preventing malaria (pre-erythrocytic)". Cochrane Database of Systematic Reviews (4): CD006198. doi:10.1002/14651858.CD006198. PMID 17054280. 
  9. ^ Stein, Rob (October 18, 2011). "Experimental malaria vaccine protects many children, study shows". Washington Post. 
  10. ^ Regules, Jason A; Cummings, James F; Ockenhouse, Christian F (2011). "The RTS,S vaccine candidate for malaria". Expert Review of Vaccines. 10 (5): 589–99. doi:10.1586/erv.11.57. PMID 21604980. 
  11. ^ "First malaria vaccine receives positive scientific opinion from EMA". European Medicines Agency. 24 July 2015. Retrieved 24 July 2015. 
  12. ^ Birkett, Ashley (September 16, 2016). "A vaccine for malaria elimination?". PATH. 
  13. ^ Regules JA, Cicatelli SB, Bennett JW, et al. (2016). "Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study". J. Infect. Dis. 214 (5): 762–71. doi:10.1093/infdis/jiw237. PMID 27296848. 
  14. ^ http://www.who.int/immunization/research/development/malaria_vaccine_qa/en/
  15. ^ RTS,S Clinical Trials Partnership (2015). "Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial". Lancet. 386 (9988): 31–45. doi:10.1016/S0140-6736(15)60721-8. PMID 25913272. 
  16. ^ Foquet, Lander; Hermsen, Cornelus; van Gemert, Geert-Jan; Van Braeckel, Eva; Weening, Karin; Sauerwein, Robert; Meuleman, Philip; Leroux-Roels, Geert (2014). "Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection". Journal of Clinical Investigation. 124 (1): 140–4. doi:10.1172/JCI70349. PMC 3871238Freely accessible. PMID 24292709. 
  17. ^ Swearingen, Kristian E.; Lindner, Scott E.; Shi, Lirong; Shears, Melanie J.; Harupa, Anke; Hopp, Christine S.; Vaughan, Ashley M.; Springer, Timothy A.; Moritz, Robert L.; Kappe, Stefan H. I.; Sinnis, Photini (29 April 2016). "Interrogating the Plasmodium Sporozoite Surface: Identification of Surface-Exposed Proteins and Demonstration of Glycosylation on CSP and TRAP by Mass Spectrometry-Based Proteomics". PLOS Pathogens. 12 (4): e1005606. doi:10.1371/journal.ppat.1005606. ISSN 1553-7374. 
  18. ^ Lopaticki, Sash; Yang, Annie S. P.; John, Alan; Scott, Nichollas E.; Lingford, James P.; O’Neill, Matthew T.; Erickson, Sara M.; McKenzie, Nicole C.; Jennison, Charlie; Whitehead, Lachlan W.; Douglas, Donna N.; Kneteman, Norman M.; Goddard-Borger, Ethan D.; Boddey, Justin A. doi:10.1038/s41467-017-00571-y. ISSN 2041-1723 https://www.nature.com/articles/s41467-017-00571-y.  Missing or empty |title= (help)
  19. ^ Swearingen, Kristian E.; Lindner, Scott E.; Flannery, Erika L.; Vaughan, Ashley M.; Morrison, Robert D.; Patrapuvich, Rapatbhorn; Koepfli, Cristian; Muller, Ivo; Jex, Aaron; Moritz, Robert L.; Kappe, Stefan H. I.; Sattabongkot, Jetsumon; Mikolajczak, Sebastian A. (31 July 2017). "Proteogenomic analysis of the total and surface-exposed proteomes of Plasmodium vivax salivary gland sporozoites". PLOS Neglected Tropical Diseases. 11 (7): e0005791. doi:10.1371/journal.pntd.0005791. ISSN 1935-2735. 


  • Wilby, K. J.; Lau, T. T.; Gilchrist, S. E.; Ensom, M. H. (2012). "Mosquirix (RTS,S): A Novel Vaccine for the Prevention of Plasmodium falciparum Malaria". Annals of Pharmacotherapy. 46 (3): 384–93. doi:10.1345/aph.1Q634. PMID 22408046. 
  • Asante, Kwaku Poku; et al. (2011). "Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial". The Lancet Infectious Diseases. 11 (10): 741–9. doi:10.1016/S1473-3099(11)70100-1. PMID 21782519. 

External links[edit]